ADMA vs. SMMT, GMAB, ITCI, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and BBIO
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.
ADMA Biologics vs. Its Competitors
Summit Therapeutics (NASDAQ:SMMT) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Summit Therapeutics presently has a consensus target price of $35.09, indicating a potential upside of 63.06%. ADMA Biologics has a consensus target price of $27.67, indicating a potential upside of 54.39%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than ADMA Biologics.
ADMA Biologics received 101 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 72.05% of users gave ADMA Biologics an outperform vote while only 58.26% of users gave Summit Therapeutics an outperform vote.
4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summit Therapeutics has a beta of -1.06, suggesting that its stock price is 206% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
In the previous week, Summit Therapeutics and Summit Therapeutics both had 8 articles in the media. Summit Therapeutics' average media sentiment score of 0.74 beat ADMA Biologics' score of 0.34 indicating that Summit Therapeutics is being referred to more favorably in the media.
ADMA Biologics has a net margin of 45.01% compared to Summit Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 47.16% beat Summit Therapeutics' return on equity.
ADMA Biologics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
ADMA Biologics beats Summit Therapeutics on 12 of the 17 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADMA Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:ADMA) was last updated on 6/24/2025 by MarketBeat.com Staff
Buy ADMA Stock Free ADMA Stock Alerts